Bausch Health Cos (BHC) Competitors

$4.66 -0.11 (-2.20%)

Closing price 03:59 PM Eastern

Extended Trading

$4.64 -0.02 (-0.45%)

As of 06:51 PM Eastern

BHC vs. IBRX, PRAX, KYMR, PTGX, and SYRE

Should you buy Bausch Health Cos stock or one of its competitors? MarketBeat compares Bausch Health Cos with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bausch Health Cos include ImmunityBio (IBRX), Praxis Precision Medicines (PRAX), Kymera Therapeutics (KYMR), Protagonist Therapeutics (PTGX), and Spyre Therapeutics (SYRE). These companies are all part of the "pharmaceutical products" industry.

How does Bausch Health Cos compare to ImmunityBio?

ImmunityBio (NASDAQ:IBRX) and Bausch Health Cos (NYSE:BHC) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends.

ImmunityBio has a beta of 0.03, indicating that its stock price is 97% less volatile than the broader market. Comparatively, Bausch Health Cos has a beta of 0.4, indicating that its stock price is 60% less volatile than the broader market.

8.6% of ImmunityBio shares are held by institutional investors. Comparatively, 78.7% of Bausch Health Cos shares are held by institutional investors. 66.1% of ImmunityBio shares are held by company insiders. Comparatively, 20.7% of Bausch Health Cos shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Bausch Health Cos has a net margin of -11.47% compared to ImmunityBio's net margin of -606.15%. ImmunityBio's return on equity of 0.00% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-606.15%	N/A	-59.53%
Bausch Health Cos	-11.47%	-2,922.77%	5.63%

Bausch Health Cos has higher revenue and earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$113.29M	66.75	-$351.40M	-$0.85	N/A
Bausch Health Cos	$10.27B	0.17	$157M	-$3.24	N/A

ImmunityBio currently has a consensus target price of $14.20, suggesting a potential upside of 96.68%. Bausch Health Cos has a consensus target price of $8.00, suggesting a potential upside of 71.49%. Given ImmunityBio's stronger consensus rating and higher possible upside, analysts clearly believe ImmunityBio is more favorable than Bausch Health Cos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Bausch Health Cos	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

In the previous week, ImmunityBio had 1 more articles in the media than Bausch Health Cos. MarketBeat recorded 1 mentions for ImmunityBio and 0 mentions for Bausch Health Cos. Bausch Health Cos' average media sentiment score of 1.87 beat ImmunityBio's score of 0.10 indicating that Bausch Health Cos is being referred to more favorably in the news media.

Company	Overall Sentiment
ImmunityBio	Neutral
Bausch Health Cos	Very Positive

Summary

ImmunityBio and Bausch Health Cos tied by winning 8 of the 16 factors compared between the two stocks.

How does Bausch Health Cos compare to Praxis Precision Medicines?

Bausch Health Cos (NYSE:BHC) and Praxis Precision Medicines (NASDAQ:PRAX) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.

In the previous week, Praxis Precision Medicines had 7 more articles in the media than Bausch Health Cos. MarketBeat recorded 7 mentions for Praxis Precision Medicines and 0 mentions for Bausch Health Cos. Bausch Health Cos' average media sentiment score of 1.87 beat Praxis Precision Medicines' score of 0.67 indicating that Bausch Health Cos is being referred to more favorably in the media.

Company	Overall Sentiment
Bausch Health Cos	Very Positive
Praxis Precision Medicines	Positive

Bausch Health Cos has a beta of 0.4, indicating that its share price is 60% less volatile than the broader market. Comparatively, Praxis Precision Medicines has a beta of 2.71, indicating that its share price is 171% more volatile than the broader market.

Bausch Health Cos currently has a consensus target price of $8.00, suggesting a potential upside of 71.49%. Praxis Precision Medicines has a consensus target price of $566.21, suggesting a potential upside of 86.63%. Given Praxis Precision Medicines' stronger consensus rating and higher probable upside, analysts clearly believe Praxis Precision Medicines is more favorable than Bausch Health Cos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch Health Cos	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	4 Strong Buy rating(s)	2.95

Bausch Health Cos has higher revenue and earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch Health Cos	$10.27B	0.17	$157M	-$3.24	N/A
Praxis Precision Medicines	$8.55M	989.30	-$303.27M	-$13.37	N/A

Praxis Precision Medicines has a net margin of 0.00% compared to Bausch Health Cos' net margin of -11.47%. Praxis Precision Medicines' return on equity of -43.02% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch Health Cos	-11.47%	-2,922.77%	5.63%
Praxis Precision Medicines	N/A	-43.02%	-40.22%

78.7% of Bausch Health Cos shares are held by institutional investors. Comparatively, 67.8% of Praxis Precision Medicines shares are held by institutional investors. 20.7% of Bausch Health Cos shares are held by company insiders. Comparatively, 3.0% of Praxis Precision Medicines shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Praxis Precision Medicines beats Bausch Health Cos on 9 of the 17 factors compared between the two stocks.

How does Bausch Health Cos compare to Kymera Therapeutics?

Kymera Therapeutics (NASDAQ:KYMR) and Bausch Health Cos (NYSE:BHC) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, media sentiment, earnings, analyst recommendations and profitability.

Kymera Therapeutics has a beta of 2.02, suggesting that its stock price is 102% more volatile than the broader market. Comparatively, Bausch Health Cos has a beta of 0.4, suggesting that its stock price is 60% less volatile than the broader market.

Kymera Therapeutics presently has a consensus target price of $117.14, suggesting a potential upside of 17.78%. Bausch Health Cos has a consensus target price of $8.00, suggesting a potential upside of 71.49%. Given Bausch Health Cos' higher possible upside, analysts clearly believe Bausch Health Cos is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.96
Bausch Health Cos	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Bausch Health Cos has a net margin of -11.47% compared to Kymera Therapeutics' net margin of -611.94%. Kymera Therapeutics' return on equity of -24.71% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-611.94%	-24.71%	-22.05%
Bausch Health Cos	-11.47%	-2,922.77%	5.63%

78.7% of Bausch Health Cos shares are held by institutional investors. 16.0% of Kymera Therapeutics shares are held by company insiders. Comparatively, 20.7% of Bausch Health Cos shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Kymera Therapeutics had 4 more articles in the media than Bausch Health Cos. MarketBeat recorded 4 mentions for Kymera Therapeutics and 0 mentions for Bausch Health Cos. Bausch Health Cos' average media sentiment score of 1.87 beat Kymera Therapeutics' score of 1.71 indicating that Bausch Health Cos is being referred to more favorably in the news media.

Company	Overall Sentiment
Kymera Therapeutics	Very Positive
Bausch Health Cos	Very Positive

Bausch Health Cos has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	208.64	-$311.35M	-$3.57	N/A
Bausch Health Cos	$10.27B	0.17	$157M	-$3.24	N/A

Summary

Bausch Health Cos beats Kymera Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Bausch Health Cos compare to Protagonist Therapeutics?

Protagonist Therapeutics (NASDAQ:PTGX) and Bausch Health Cos (NYSE:BHC) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Bausch Health Cos has a net margin of -11.47% compared to Protagonist Therapeutics' net margin of -154.88%. Protagonist Therapeutics' return on equity of -17.76% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%
Bausch Health Cos	-11.47%	-2,922.77%	5.63%

98.6% of Protagonist Therapeutics shares are held by institutional investors. Comparatively, 78.7% of Bausch Health Cos shares are held by institutional investors. 5.2% of Protagonist Therapeutics shares are held by insiders. Comparatively, 20.7% of Bausch Health Cos shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Protagonist Therapeutics has a beta of 1.86, meaning that its stock price is 86% more volatile than the broader market. Comparatively, Bausch Health Cos has a beta of 0.4, meaning that its stock price is 60% less volatile than the broader market.

In the previous week, Protagonist Therapeutics had 5 more articles in the media than Bausch Health Cos. MarketBeat recorded 5 mentions for Protagonist Therapeutics and 0 mentions for Bausch Health Cos. Bausch Health Cos' average media sentiment score of 1.87 beat Protagonist Therapeutics' score of 1.30 indicating that Bausch Health Cos is being referred to more favorably in the news media.

Company	Overall Sentiment
Protagonist Therapeutics	Positive
Bausch Health Cos	Very Positive

Bausch Health Cos has higher revenue and earnings than Protagonist Therapeutics. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$46.02M	160.75	-$130.15M	-$1.81	N/A
Bausch Health Cos	$10.27B	0.17	$157M	-$3.24	N/A

Protagonist Therapeutics presently has a consensus price target of $115.21, suggesting a potential upside of 0.16%. Bausch Health Cos has a consensus price target of $8.00, suggesting a potential upside of 71.49%. Given Bausch Health Cos' higher possible upside, analysts clearly believe Bausch Health Cos is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Bausch Health Cos	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Summary

Protagonist Therapeutics beats Bausch Health Cos on 9 of the 17 factors compared between the two stocks.

How does Bausch Health Cos compare to Spyre Therapeutics?

Bausch Health Cos (NYSE:BHC) and Spyre Therapeutics (NASDAQ:SYRE) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, media sentiment, dividends and valuation.

Spyre Therapeutics has a net margin of 0.00% compared to Bausch Health Cos' net margin of -11.47%. Spyre Therapeutics' return on equity of -42.88% beat Bausch Health Cos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch Health Cos	-11.47%	-2,922.77%	5.63%
Spyre Therapeutics	N/A	-42.88%	-27.76%

In the previous week, Spyre Therapeutics had 8 more articles in the media than Bausch Health Cos. MarketBeat recorded 8 mentions for Spyre Therapeutics and 0 mentions for Bausch Health Cos. Bausch Health Cos' average media sentiment score of 1.87 beat Spyre Therapeutics' score of 0.35 indicating that Bausch Health Cos is being referred to more favorably in the media.

Company	Overall Sentiment
Bausch Health Cos	Very Positive
Spyre Therapeutics	Neutral

78.7% of Bausch Health Cos shares are held by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are held by institutional investors. 20.7% of Bausch Health Cos shares are held by company insiders. Comparatively, 15.7% of Spyre Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Bausch Health Cos has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Bausch Health Cos, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch Health Cos	$10.27B	0.17	$157M	-$3.24	N/A
Spyre Therapeutics	$890K	9,788.53	-$155.20M	-$2.08	N/A

Bausch Health Cos currently has a consensus target price of $8.00, indicating a potential upside of 71.49%. Spyre Therapeutics has a consensus target price of $94.17, indicating a potential downside of 6.13%. Given Bausch Health Cos' higher probable upside, equities analysts plainly believe Bausch Health Cos is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch Health Cos	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

Bausch Health Cos has a beta of 0.4, meaning that its share price is 60% less volatile than the broader market. Comparatively, Spyre Therapeutics has a beta of 3.05, meaning that its share price is 205% more volatile than the broader market.

Summary

Spyre Therapeutics beats Bausch Health Cos on 10 of the 17 factors compared between the two stocks.

Get Bausch Health Cos News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BHC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BHC vs. The Competition

Export

Metric	Bausch Health Cos	MED Industry	Medical Sector	NYSE Exchange
Market Cap	$1.74B	$5.77B	$6.42B	$23.29B
Dividend Yield	N/A	0.69%	2.68%	4.06%
P/E Ratio	-1.44	8.47	24.82	31.48
Price / Sales	0.17	23.84	571.82	22.50
Price / Cash	0.65	8.19	27.92	18.67
Price / Book	4.57	4.14	10.85	4.68
Net Income	$157M	$99.67M	$3.56B	$1.08B
7 Day Performance	-6.23%	1.51%	0.70%	-1.09%
1 Month Performance	-14.64%	1.02%	0.29%	0.29%
1 Year Performance	-24.39%	121.35%	30.68%	24.73%

Bausch Health Cos Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BHC Bausch Health Cos	2.9637 of 5 stars	$4.67 -2.2%	$8.00 +71.5%	-22.9%	$1.74B	$10.27B	N/A	20,300	Positive News
IBRX ImmunityBio	2.9182 of 5 stars	$7.13 +0.4%	$14.20 +99.2%	+156.4%	$7.44B	$113.29M	N/A	590
PRAX Praxis Precision Medicines	2.7914 of 5 stars	$264.54 -0.8%	$572.72 +116.5%	+566.8%	$7.43B	$8.55M	N/A	110	News Coverage
KYMR Kymera Therapeutics	1.9602 of 5 stars	$85.59 -0.7%	$117.14 +36.9%	+97.1%	$7.09B	$39.21M	N/A	170	Positive News Gap Up
PTGX Protagonist Therapeutics	1.4152 of 5 stars	$112.46 +2.4%	$115.21 +2.4%	+111.6%	$7.06B	$46.02M	N/A	120	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:BHC) was last updated on 6/22/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bausch Health Cos (BHC) Competitors

BHC vs. IBRX, PRAX, KYMR, PTGX, and SYRE

How does Bausch Health Cos compare to ImmunityBio?

Summary

How does Bausch Health Cos compare to Praxis Precision Medicines?

Summary

How does Bausch Health Cos compare to Kymera Therapeutics?

Summary

How does Bausch Health Cos compare to Protagonist Therapeutics?

Summary

How does Bausch Health Cos compare to Spyre Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHC vs. The Competition

Bausch Health Cos Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bausch Health Cos (BHC) Competitors

BHC vs. IBRX, PRAX, KYMR, PTGX, and SYRE

How does Bausch Health Cos compare to ImmunityBio?

Which has more risk & volatility, IBRX or BHC?

Do institutionals & insiders hold more shares of IBRX or BHC?

Is IBRX or BHC more profitable?

Which has better valuation and earnings, IBRX or BHC?

Do analysts rate IBRX or BHC?

Does the media favor IBRX or BHC?

Summary

How does Bausch Health Cos compare to Praxis Precision Medicines?

Does the media refer more to BHC or PRAX?

Which has more volatility & risk, BHC or PRAX?

Do analysts recommend BHC or PRAX?

Which has stronger valuation & earnings, BHC or PRAX?

Is BHC or PRAX more profitable?

Do insiders and institutionals have more ownership in BHC or PRAX?

Summary

How does Bausch Health Cos compare to Kymera Therapeutics?

Which has more risk & volatility, KYMR or BHC?

Do analysts prefer KYMR or BHC?

Is KYMR or BHC more profitable?

Do institutionals and insiders have more ownership in KYMR or BHC?

Does the media prefer KYMR or BHC?

Which has higher valuation and earnings, KYMR or BHC?

Summary

How does Bausch Health Cos compare to Protagonist Therapeutics?

Is PTGX or BHC more profitable?

Do insiders and institutionals have more ownership in PTGX or BHC?

Which has more risk & volatility, PTGX or BHC?

Does the media favor PTGX or BHC?

Which has better earnings and valuation, PTGX or BHC?

Do analysts prefer PTGX or BHC?

Summary

How does Bausch Health Cos compare to Spyre Therapeutics?

Is BHC or SYRE more profitable?

Does the media refer more to BHC or SYRE?

Do insiders and institutionals believe in BHC or SYRE?

Which has stronger valuation and earnings, BHC or SYRE?

Do analysts rate BHC or SYRE?

Which has more volatility and risk, BHC or SYRE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHC vs. The Competition

Bausch Health Cos Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools